TerraBioGen Announces Cornell University Study Results

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 8, 2012) -

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.

TerraBioGen Technologies Inc. (TSX VENTURE:TBG), a developer and marketer of proprietary technologies for the production of organic-based, high-value agricultural products from organic wastes, announces the results of recent studies done by Cornell University.

The study conducted by Cornell University's Department of Horticulture was designed to assess the ability of TerraBioGen's liquid LC200, applied at several rates and intervals, to reduce golf fairway turf nutrient requirements. Standard fertilizer inputs were applied at 100, 75, 50 and 25 percent of normal rates required to produce acceptable quality turf. LC200 was applied at three rates every 7, 14, 28 and 56 days. The study showed a complex interaction between the plant and compounds in LC200, and suggests that normal fertilizer rates can be reduced as much as 75% with moderate rates of LC200 applied once every two months during the growing season. Not only does this enhance economic performance, the reduction of nutrient loading into the environment offers significant protection of water quality.

Blair Heffelfinger, President and CEO of TerraBioGen, said, "The Cornell study reaffirms previous turf grass research indicating that treatment with TerraBioGen's LC200 will allow for a significant reduction in fertilizer input without noticeably impacting turf quality. This is a win-win situation in that it provides both economic benefits to the grounds keeper and environmental benefits to society as a whole."

About TerraBioGen Technologies

Located in North Vancouver, BC, TerraBioGen Technologies Inc. is committed to research and development to continue to improve the efficiency of its technology and the quality of its agricultural products. It is further committed to developing a world-wide marketing capability to ensure market acceptance of its products.

This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen's management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.